Related Experiment Video
Updated: Jul 13, 2026
11:31
Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer
Published on: May 20, 2016
[Nitrofurantoin-induced lung disease: about two cases].
N Mrozek1, I Delèvaux, M Legendre
1Service de médecine interne, CHU Gabriel-Montpied, 58, rue Montalembert, B.P. 69, 63003 Clermont-Ferrand cedex 01, France.
La Revue De Medecine Interne
|July 28, 2007
Summary
Nitrofurantoin can cause severe lung issues like interstitial lung disease in patients with urinary tract infections. Discontinuing the drug improves respiratory symptoms, highlighting the need for careful monitoring during long-term use.
Area of Science:
- Pulmonology
- Pharmacology
- Internal Medicine
Background:
- Nitrofurantoin is a widely prescribed antibiotic for urinary tract infections (UTIs).
- Long-term nitrofurantoin use is associated with a risk of interstitial lung diseases (ILDs).
Observation:
- Two elderly women developed cough and dyspnea after prolonged nitrofurantoin treatment for UTIs.
- Initial antibiotic treatments were ineffective, and interstitial lung disease was diagnosed.
- Discontinuation of nitrofurantoin led to significant clinical and radiological improvement in both patients.
Findings:
- Nitrofurantoin-induced interstitial lung disease can manifest with respiratory symptoms after extended treatment periods.
- Prompt cessation of nitrofurantoin is crucial for managing and reversing drug-induced lung injury.
- Early recognition and intervention are key to preventing severe complications.
Implications:
- Emphasizes the importance of vigilant medical supervision for patients on long-term nitrofurantoin therapy.
- Highlights the need to consider nitrofurantoin-induced ILD in patients with unexplained respiratory symptoms.
- Supports the protocol of immediate drug withdrawal upon the appearance of pulmonary adverse effects.
Related Concept Videos
01:28Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:28Pulmonary Tuberculosis II
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:31Pulmonary Tuberculosis III
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:29Pulmonary Tuberculosis I
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...